Efficacy of Botulinum Toxin Type A in the Treatment of Focal Axillary Hyperhidrosis

Absar, Mohammed; Onwudike, Madu

doi:10.1111/j.1524-4725.2008.34142.x

Cited by 14 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mostly, such measurements were performed in dermatological settings and concerned the results of botox treatment [3, 4, 13–17, 19] or iontophoresis [12]. In those methods of treatment, associated with low level of transient complications or side effects, even less stringent approach to qualification will not cause long-term harm to the patients.…”

Section: Discussionmentioning

confidence: 99%

Gravimetry in sweating assessment in primary hyperhidrosis and healthy individuals

Stefaniak

Proczko

2013

Clin Auton Res

View full text Add to dashboard Cite

ObjectiveThough hyperhidrosis is generally considered a subjectively perceived disease, it seems more and more doubtful that merely subjective evaluation is sufficient to qualify the patient to surgery. The aim of this study was to develop further gravimetry as a method of evaluation of sweating intensity and determination of the applicability of it in post-operative follow-up of primary hyperhidrosis (PHH) patients.MethodsTotal of 1,485 gravimetry assays has been performed in 343 patients treated for hyperhidrosis and in 220 healthy volunteers. In all of the subjects the measurements were taken from four localizations (face, hands, armpits and trunk) and normalized by body surface of the participant. The measurements were taken twice for every participant to obtain test–retest correlations. Mean values and standard deviations (SD) have been evaluated and on that basis reference values were quantified. Thresholds for diagnosis of hyperhidrosis were quantified on the basis of normal distribution theory as healthy population mean +2 SD.ResultsIn healthy volunteers, mean value of gravimetrically evaluated intensity of sweating were: facial: 19.15 ± 14.97 mg/min/m2, palmar: 18.49 ± 14.06 mg/min/m2, axillary: 42.39 ± 47.08 mg/min/m2 and plantar: 15.77 ± 16.87 mg/min/m2. Thresholds for diagnosis of hyperhidrosis were quantified, respectively as: 49, 46, 136 and 50 mg/min/m2. The overall test–retest correlation was 0.71.InterpretationGravimetry is easy, reproducible and fast method of evaluation of sweating. The reference values are stable and can serve as a qualifying and follow-up tool for evaluation of the patients with PHH in any localization.

show abstract

Section: Discussionmentioning

confidence: 99%

Gravimetry in sweating assessment in primary hyperhidrosis and healthy individuals

Stefaniak

Proczko

2013

Clin Auton Res

View full text Add to dashboard Cite

show abstract

“…This condition causes significant problems both in social and private daily life and affects about 2.5% of the population [6, 7]. …”

Section: Introductionmentioning

confidence: 99%

Treatment of Primary Axillary Hyperhidrosis with Botulinum Toxin Type A: Our Experience in 50 Patients from 2007 to 2010

et al. 2012

View full text Add to dashboard Cite

Background. Local injections of Botulinum toxin type A (BTX-A) are an effective and safe solution for primary bilateral axillary hyperhidrosis. Traditional treatments are often ineffective and difficult to tolerate. This study was performed to assess the efficacy and safety of Botulinum toxin type A in the treatment of these diseases and to evaluate the reliability of patient's subjective rating in the timing of repeat injections. Methods. From 2007 to 2008, we included in the study and treated a total of 50 patients, and we used the Minor's iodine test and the hyperhidrosis diseases severity scale as initial inclusion criteria and also for evaluating the followup, comparing to patient's subjective rating. We used also a specific questionnaire to evaluate the level of pain, the onset of the effect, any eventual adverse effect of the treatment, the onset of compensatory hyperhidrosis, and the global grade of satisfaction. The data were analyzed using standard statistical methods. Results. 88% of patients were totally satisfied and all patients repeated the treatment during all the study. The symptom-free interval was in median 6 months with an average improving of HDSS of 1.5 points. In 86%, there was a complete accordance between the subjective patient's demand of the repetition of the treatment and the positivity to Minor test and HDSS. No major side effects happened. Conclusion. Local injections of Botulinum toxin type A (BTX-A) result in an effective and safe solution for bilateral axillary primary hyperhidrosis for the absence of significant morbidity, side effects, and lack of efficacy or duration. The only defects are the need of repetition of the treatment and relative costs.

show abstract

“…5,7 In conclusion, these preliminary findings show that female patients with idiopathic axillary hyperhidrosis who have lower gravimetric sweat test results could benefit from 35 U of BonTA as a reasonable starting dose which contributes significantly to improving patients' QOL as well as significantly reducing the cost of treatment.…”

Section: Discussionmentioning

confidence: 92%

“…Although there is no placebo comparison used in this study, other literature has shown that placebo has a much lower response rate of 33%. 1,5,7 Subjectively, 55% of patients had significant improvement in their QOL to the point that their hyperhidrosis had little or no impact on them.…”

Section: Discussionmentioning

confidence: 97%

Thirty-five units of botulinum toxin type A for treatment of axillary hyperhidrosis in female patients

Marcella

Goodman

Cumming

et al. 2011

Australasian Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Efficacy of Botulinum Toxin Type A in the Treatment of Focal Axillary Hyperhidrosis

Cited by 14 publications

References 21 publications

Gravimetry in sweating assessment in primary hyperhidrosis and healthy individuals

Gravimetry in sweating assessment in primary hyperhidrosis and healthy individuals

Treatment of Primary Axillary Hyperhidrosis with Botulinum Toxin Type A: Our Experience in 50 Patients from 2007 to 2010

Thirty-five units of botulinum toxin type A for treatment of axillary hyperhidrosis in female patients

Contact Info

Product

Resources

About